LAT and non-small cell lung carcinoma: In addition to this study, Weickhardt et al. examined LAT for oligo-progressive disease, including brain and extra-CNS lesions, in 25 pts with EGFR-mutated or ALK-rearranged NSCLC who progressed on erlotinib or crizotinib and were judged to be suitable for LAT [31].